专利检索 ipc:"C07D311/56" 第 1 页

1.

发明公开
COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS 审中-公开

公开(公告)号：US20240100199A1

公开(公告)日：2024-03-28

申请号：US18352435

申请日：2023-07-14

申请人： Lantheus Medical Imaging, Inc.

发明人： Richard R. Cesati , Heike S. Radeke , Suresh K. Pandey , Ajay Purohit , Simon P. Robinson

IPC分类号： A61K51/04 , C07D311/56 , C07D401/12 , C07D237/14 , C07D237/16 , C07B59/00 , C07F7/08 , A61K49/00 , B01J19/24 , C07D237/04 , C07D403/12 , C07F7/12

CPC分类号： A61K51/0459 , C07D311/56 , C07D401/12 , C07D237/14 , C07D237/16 , C07B59/002 , C07F7/0812 , A61K49/0004 , B01J19/24 , C07D237/04 , C07D403/12 , C07F7/12 , B01J2219/24 , C07B2200/05

摘要： The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

2.

发明授权
O-substituted hydroxamic acids 有权

公开(公告)号：US10913728B2

公开(公告)日：2021-02-09

申请号：US16321378

申请日：2017-07-27

申请人： The Johns Hopkins University , John P. Toscano , Saghar Nourian , Daryl A. Guthrie

发明人： John P. Toscano , Saghar Nourian , Daryl A. Guthrie

IPC分类号： C07D311/56 , C07D239/62 , C07D231/28 , A61P9/10

摘要： O-substituted hydroxamic acids with carbon-based leaving groups as HNO donors are disclosed. Pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions also are disclosed.

3.

发明申请
POGOSTONE DERIVATIVES AND METHODS OF USING THE SAME 审中-公开

公开(公告)号：US20200024246A1

公开(公告)日：2020-01-23

申请号：US16518550

申请日：2019-07-22

申请人： Hamyard Associates LLC

发明人： George A. Kraus , Joel R. Coats , Edmund J. Norris

IPC分类号： C07D309/38 , C07D493/04 , C07D215/20 , C07C49/788 , C07C49/248 , C07D311/56 , C07D407/06 , C07C49/203 , C07D233/96 , C07D413/06 , A01N43/80 , A01N43/50 , A01N43/16 , A01N31/16 , A01N43/28

摘要： Described are novel derivatives of pogostone and methods of using the same.

4.

发明申请
COMPOSITION AND RODENTICIDAL BAIT COMPRISING FLOCOUMAFEN, AND PROCESS FOR CONTROLLING TARGET RODENT PESTS 审中-公开

公开(公告)号：US20180362489A1

公开(公告)日：2018-12-20

申请号：US16061115

申请日：2016-12-06

申请人： LIPHATECH , INSTITUT ENSEIGNEMENT SUPERIEUR ET RECHERCHE EN ALIMENTATION SANTE ANIMALE SCIENCES AGRONOMIQUES E

发明人： Hervé CARUEL , Etienne BENOIT , Isabelle FOUREL , Virginie LATTARD

IPC分类号： C07D311/56 , A01N43/16 , A01N25/00

摘要： Disclosed is a composition including flocoumafen and an amount of a configurational stereoisomer of flocoumafen, named enantiomer E4, such that the ratio of this amount to the amount of flocoumafen in the composition is less than 10%, the enantiomer E4 being present with the exclusion of a racemic mixture, the enantiomer E4 having, by chromatographic analysis of flocoumafen, a retention time t4 having a value such that t1

5.

发明申请
STEREOISOMER OF FLOCOUMAFEN, COMPOSITION AND RODENTICIDE BAIT COMPRISING SAME, AND METHOD FOR CONTROLLING TARGET RODENT PESTS 审中-公开

公开(公告)号：US20180362488A1

公开(公告)日：2018-12-20

申请号：US16061092

申请日：2016-12-06

申请人： LIPHATECH , INSTITUT ENSEIGNEMENT SUPERIEUR ET RECHERCHE EN ALIMENTATION SANTE ANIMALE SCIENCES AGRONOMIQUES

发明人： Hervé CARUEL , Etienne BENOIT , Isabelle FOUREL , Virginie LATTARD

IPC分类号： C07D311/56 , A01N43/16 , A01N25/00

摘要： Disclosed is a configurational stereoisomer, referred to as enantiomer E2, of flocoumafen, the enantiomer E2 having, as determined by the chromatographic analysis of a flocoumafen composition including four configurational stereoisomers of flocoumafen, carried out under conditions described hereinafter, a retention time t2 with a value such that t1

6.

发明申请
COMPOUND DIVERSIFICATION USING LATE STAGE FUNCTIONALIZATION 审中-公开
标题翻译：使用最后阶段功能化的化合物多样化

公开(公告)号：US20150274755A1

公开(公告)日：2015-10-01

申请号：US14431134

申请日：2013-09-20

申请人： Shane W. KRSKA , Petr VACHAL , Christopher J. WELCH , Graham F. SMITH , MERCK SHARP & DOHME CORP.

发明人： Shane W. Krska , Petr Vachal , Christopher J. Welch , Graham F. Smith

IPC分类号： C07F5/02 , C07D311/56

CPC分类号： C07C17/10 , C07C17/013 , C07D311/56 , C07F5/025 , C40B40/04 , C40B50/08

摘要： The present invention relates to methods for generating limited chemical diversity for biologically relevant lead molecules by late state functionalization, separation, and post-functionalization modification. The methods optionally include one or more screening steps. Traditional drug development has relied on the synthesis of individual compounds or the generation of large chemical libraries, but these methods have generally been fairly inefficient in obtaining drug products.

摘要翻译： 本发明涉及通过后期官能化，分离和后官能化修饰产生生物相关铅分子的有限化学多样性的方法。方法可选地包括一个或多个筛选步骤。传统药物开发依赖于单个化合物的合成或大量化学文库的产生，但这些方法在获得药物产品方面通常相当低效。

7.

发明申请
POLYMORPHIC FORMS OF WARFARIN POTASSIUM AND PREPARATIONS THEREOF 失效
标题翻译：多形态多糖形式及其制备方法

公开(公告)号：US20130143957A1

公开(公告)日：2013-06-06

申请号：US13699293

申请日：2011-05-20

申请人： Prabhudas Bodhuri , Gamini Weeratunga , Keshava K.S. Murthy

发明人： Prabhudas Bodhuri , Gamini Weeratunga , Keshava K.S. Murthy

IPC分类号： A61K31/365 , C07D311/56 , C07D311/06

CPC分类号： C07D311/56

摘要： There is provided crystalline solvate forms of Warfarin potassium, termed APO-I and APO-II, and processes for making APO-I and APO-II. APO-I and APO-II are polymorphic solvate forms of Warfarin potassium.

摘要翻译： 提供了称为APO-1和APO-II的华法林钾的结晶溶剂化物形式，以及制备APO-1和APO-II的方法。 APO-I和APO-II是华法林钾的多晶型溶剂合物形式。

8.

发明授权
Halogenated ester derivatives of coumarins for the treatment of coagulation disorders 有权
标题翻译：香豆素的卤代酯衍生物用于治疗凝血障碍

公开(公告)号：US07932405B2

公开(公告)日：2011-04-26

申请号：US12268109

申请日：2008-11-10

申请人： Pascal Druzgala , Cyrus Becker

发明人： Pascal Druzgala , Cyrus Becker

IPC分类号： C07D311/56 , A61K31/352

CPC分类号： C07D311/56

摘要： The subject invention provides anticoagulant compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The invention further comprises pharmaceutical compositions comprising the compounds and salts of the invention, as well as methods of using the compounds, salts, and compositions of the invention.

摘要翻译： 本发明提供了式I的抗凝血剂化合物及其药学上可接受的盐，其中R 1，R 3，n和Ar如本文所定义。本发明的化合物可用于治疗危险人群，从而缓解症状，改善生活质量，预防急性和长期并发症，降低死亡率和治疗伴随的疾病。本发明还包括包含本发明化合物和盐的药物组合物，以及使用本发明化合物，盐和组合物的方法。

9.

发明申请
Production of isoflavone derivatives 审中-公开
标题翻译：异黄酮衍生物的生产

公开(公告)号：US20050143588A1

公开(公告)日：2005-06-30

申请号：US10851270

申请日：2004-05-20

申请人： Andrew Heaton , Naresh Kumar

发明人： Andrew Heaton , Naresh Kumar

IPC分类号： C07B61/00 , C07D311/36 , C07D311/38 , C07D311/56 , C07D311/58 , C07D311/74

CPC分类号： C07D311/56 , C07D311/36 , C07D311/38

摘要： Methods for the hydrogenation of isoflavones are described which provide access to workable quantities of isoflavan-4-ols, isoflav-3-enes, and isoflavans. The isoflavone derivatives can be obtained in high purity and in near quantitative yields whilst employing pharmaceutically acceptable reagents and solvents.

摘要翻译： 描述了异黄酮氢化方法，其提供了可使用量的异黄烷-4-醇，异氟烷-3-烯和异构体。异黄酮衍生物可以以高纯度和接近定量的产率获得，同时使用药学上可接受的试剂和溶剂。